Emerging Clinical Evidence and Future Role of CELMoDs in Multiple Myeloma

The closing discussion brings together the emerging clinical evidence and future development of CELMoDs in multiple myeloma. Dr. Richardson discusses investigational mezigdomide-based approaches in heavily pretreated patients, including experience with mezigdomide plus dexamethasone and ongoing combination studies. The panel reviews findings from the SUCCESSOR-2 study, including progression-free survival and activity observed across selected patient subgroups, while emphasizing the continued investigational status of mezigdomide. The discussion also highlights the importance of safety and treatment tolerability when considering CELMoDs for patients with advanced multiple myeloma, particularly as treatment options increasingly include T-cell-engaging therapies. Dr. Richardson notes the availability of ongoing clinical trials and expanded-access opportunities for eligible patients. Dr. Mikhael then summarizes the program by revisiting the CELMoD mechanism, distinctions from established IMiDs, and the emerging clinical evidence supporting continued development of this therapeutic class.